Clinical Trial Update: 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating 68Ga-HA-DOTATATE PET imaging for suspected somatostatin receptor–positive neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• 68Ga-HA-DOTATATE (Ga-68 DOTATATE radiotracer)

Snippet

Sponsor: University of Alberta | Conditions: Neuroendocrine Tumors | Phase 2 | Status: RECRUITING